WS #15852
Viking Therapeutics initiated the SUNRISE Phase 3 clinical program for VK2735, an oral dual agonist of GLP-1 and GIP receptors for obesity treatment, joining the competitive weight-loss drug market. Parabilis Medicines advanced its zolucatetide trial for familial adenomatous polyposis, showing early promise in inhibiting tumor growth. These developments provide targeted catalysts for biotech investors, though Viking faces stiff competition from established players in the GLP-1 space.
Biotech Clinical Catalysts
Viking Therapeutics initiated the SUNRISE Phase 3 clinical program for VK2735, an oral dual agonist of GLP-1 and GIP receptors for obesity treatment, joining the competitive weight-loss drug market. Parabilis Medicines advanced its zolucatetide trial for familial adenomatous polyposis, showing early promise in inhibiting tumor growth. These developments provide targeted catalysts for biotech investors, though Viking faces stiff competition from established players in the GLP-1 space.